Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study.

Journal: The Lancet. Rheumatology
PMID: 38251497

Abstract

BACKGROUND: An adalimumab biosimilar with an interchangeability designation could increase access to effective treatment for more patients. We aimed to assess the interchangeability of adalimumab biosimilar PF-06410293 (adalimumab-afzb) and reference adalimumab using a multi-switch study design.

Authors

  • Roy M Fleischmann
    University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, USA. Electronic address: rfleischmann@dfwra.com.
  • Wassim Saikali
    Rheumatology and Pulmonary Clinic, Beckley, WV, USA.
  • Sharad Lakhanpal
    University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Daniel F Alvarez
    Pfizer, Collegeville, PA, USA.
  • Donna S Cox
    Pfizer, Collegeville, PA, USA.
  • Claudia Ana Ianos
    Pfizer Zürich, Switzerland.
  • Wuyan Zhang
    Pfizer, Lake Forest, IL, USA.
  • Carol Cronenberger
    Pfizer, Collegeville, PA, USA.
  • Karen Wang
    Pfizer, La Jolla, CA, USA.

Keywords

External Resources

Popular Topics
Recent Journals